SANA · NASDAQ · Biotechnology

Sana Biotechnology (SANA)

Engineers immune-evading cells and in vivo CAR T therapies for diabetes and B-cell disease.

$3.05
vs last close−0.28 (−8.45%)

Something off on this page? Send us feedback.

Next report
Nov 5, 26
estimated · in 43 days
EPS estimate
−$0.18
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.23−$0.20−$0.39−$0.15−$0.16−$0.14−$0.22Pending
Estimate−$0.25−$0.22−$0.20−$0.18−$0.13−$0.15−$0.15−$0.18
Surprise+8.0%+9.1%−95.0%+16.7%−23.1%+6.7%−49.8%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.15
Sep 2027−$0.15
Jun 2027−$0.14
Mar 2027−$0.15
Dec 2026−$0.17
Nov 2026−$0.18
Aug 2026−$0.15−$0.22−49.8%
May 2026−$0.15−$0.14+6.7%
Mar 2026−$0.13−$0.16−23.1%
Nov 2025−$0.18−$0.15+16.7%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Feb 2021
Jun 2020
Mar 2020
Dec 2019

The latest year is open to everyone — the 23 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.15$0
Sep 2027−$0.15$0
Jun 2027−$0.14$0
Mar 2027−$0.15$0
Dec 2026−$0.17$0
Nov 5, 2026−$0.18$0
Aug 11, 2026−$0.15−$0.22−49.8%−0.5%
May 11, 2026−$0.15−$0.14+6.7%+1.4%
Mar 3, 2026−$0.13−$0.16−23.1%−2.8%
Nov 6, 2025−$0.18−$0.15+16.7%−0.7%
Aug 11, 2025
May 8, 2025
Mar 17, 2025
Nov 8, 2024
Aug 8, 2024
May 8, 2024
Feb 29, 2024
Nov 8, 2023
Aug 3, 2023
May 8, 2023
Mar 16, 2023
Nov 2, 2022
Aug 4, 2022
May 10, 2022
Mar 16, 2022
Nov 8, 2021
Aug 4, 2021
May 5, 2021
Mar 24, 2021
Feb 5, 2021
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019

The latest year is open to everyone — the 23 quarters behind it read with an account.